Luye Pharma Group Ltd. (02186.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	12.3B	6.3B	6.1B	6.1B	6.0B
Cost of Revenue	4.3B	2.1B	2.0B	1.9B	1.8B
Gross Profit	8.0B	4.2B	4.0B	4.2B	4.1B
Operating Expenses
R&D Expense	884.9M	413.9M	498.6M	586.2M	857.3M
SG&A Expense	4.6B	2.5B	2.4B	2.7B	2.4B
General & Admin Expense	972.4M	679.6M	582.0M	644.0M	582.9M
Selling & Marketing Expense	2.8B	1.8B	1.8B	2.1B	1.8B
Other Expenses	—	—	—	—	—
Total Operating Expenses	5.5B	2.9B	2.9B	3.3B	3.3B
Cost and Expenses	9.8B	5.1B	4.9B	5.2B	5.1B
Operating Income (EBIT)	2.5B	1.2B	1.1B	917.9M	880.6M
Non-Operating
Interest Income	44.2M	96.1M	84.4M	117.1M	88.7M
Interest Expense	1.2B	686.6M	561.8M	675.5M	471.8M
Net Interest Income	(1.2B)	(590.5M)	(477.4M)	(558.3M)	(383.1M)
Other Non-Op Income/Expense	(736.7M)	(298.2M)	(308.0M)	(217.8M)	(210.9M)
Non-Operating Income (excl Interest)	105.2M	25.2M	19.1M	(346.8M)	91.5M
EBT (Pre-Tax Income)	1.8B	944.6M	839.2M	700.1M	669.8M
Income Tax Expense	474.1M	239.0M	194.2M	161.0M	86.5M
Bottom Line
Net Income	1.1B	618.7M	471.9M	532.6M	604.8M
Earnings from Cont. Ops	1.3B	705.7M	645.0M	539.1M	583.3M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	1.1B	618.7M	471.9M	532.6M	604.8M
Per Share
Basic EPS	HK$0.28	HK$0.16	HK$0.13	HK$0.14	HK$0.17
Diluted EPS	HK$0.28	HK$0.16	HK$0.13	HK$0.14	HK$0.17
Revenue Per Share	HK$3.07	HK$1.62	HK$1.61	HK$1.65	HK$1.72
Shares
Basic Shares Outstanding	4.0B	3.9B	3.8B	3.7B	3.5B
Diluted Shares Outstanding	4.0B	3.9B	3.8B	3.7B	3.5B
Profitability Metrics
EBITDA	3.9B	2.0B	1.8B	2.1B	1.8B
D&A	1.5B	796.7M	665.5M	701.9M	671.3M
EBIT	2.4B	1.2B	1.1B	1.4B	1.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026